TWI766842B - 抗真菌化合物及其製備方法 - Google Patents

抗真菌化合物及其製備方法 Download PDF

Info

Publication number
TWI766842B
TWI766842B TW105130165A TW105130165A TWI766842B TW I766842 B TWI766842 B TW I766842B TW 105130165 A TW105130165 A TW 105130165A TW 105130165 A TW105130165 A TW 105130165A TW I766842 B TWI766842 B TW I766842B
Authority
TW
Taiwan
Prior art keywords
compound
formula
anhydrous form
solvent
antifungal compound
Prior art date
Application number
TW105130165A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718540A (zh
Inventor
大衛 戴爾 威爾希
克里斯多夫Ｍ 耶茨
Original Assignee
開曼群島商Ｎｑｐ１５９８股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商Ｎｑｐ１５９８股份有限公司 filed Critical 開曼群島商Ｎｑｐ１５９８股份有限公司
Publication of TW201718540A publication Critical patent/TW201718540A/zh
Application granted granted Critical
Publication of TWI766842B publication Critical patent/TWI766842B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34—Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/341—1,2-additions, e.g. aldol or Knoevenagel condensations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW105130165A 2015-09-18 2016-09-19 抗真菌化合物及其製備方法 TWI766842B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562220384P 2015-09-18 2015-09-18
US62/220,384 2015-09-18
US201662275504P 2016-01-06 2016-01-06
US62/275,504 2016-01-06

Publications (2)

Publication Number Publication Date
TW201718540A TW201718540A (zh) 2017-06-01
TWI766842B true TWI766842B (zh) 2022-06-11

Family

ID=58289604

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105130167A TWI730986B (zh) 2015-09-18 2016-09-19 抗真菌化合物方法
TW105130165A TWI766842B (zh) 2015-09-18 2016-09-19 抗真菌化合物及其製備方法
TW105130166A TWI723047B (zh) 2015-09-18 2016-09-19 抗真菌化合物方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105130167A TWI730986B (zh) 2015-09-18 2016-09-19 抗真菌化合物方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105130166A TWI723047B (zh) 2015-09-18 2016-09-19 抗真菌化合物方法

Country Status (17)

Country Link
US (4) US10308632B2 (OSRAM)
EP (3) EP3349586B1 (OSRAM)
JP (4) JP2018532719A (OSRAM)
KR (3) KR20180053393A (OSRAM)
CN (3) CN108347949B (OSRAM)
AU (3) AU2016324148B2 (OSRAM)
BR (2) BR112018005198A2 (OSRAM)
CA (3) CA2998805C (OSRAM)
EA (3) EA038214B1 (OSRAM)
ES (2) ES2821021T3 (OSRAM)
HK (3) HK1258862A1 (OSRAM)
HU (1) HUE053638T2 (OSRAM)
MX (3) MX391539B (OSRAM)
PL (1) PL3349586T3 (OSRAM)
TW (3) TWI730986B (OSRAM)
WO (3) WO2017049096A1 (OSRAM)
ZA (1) ZA201801404B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143166A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119745B1 (en) 2014-03-19 2020-08-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3119754A4 (en) 2014-03-19 2017-12-13 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) * 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
WO2015143162A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
WO2015143154A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
WO2017049096A1 (en) 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Antifungal compound process
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
EP3710432A1 (en) 2017-11-13 2020-09-23 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
WO2021188404A1 (en) * 2020-03-19 2021-09-23 Assia Chemical Industries Ltd Solid state forms of oteseconazole and process for preparation thereof
CA3226998A1 (en) * 2021-07-22 2023-01-26 Mycovia Pharmaceuticals, Inc. Compositions comprising oteseconazole
CN114573503B (zh) * 2022-03-28 2024-04-09 浙江天宇药业股份有限公司 一种制备奥特康唑中间体的方法
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法
CN116621816B (zh) * 2022-09-23 2025-07-04 北京莱瑞森医药科技有限公司 一种伏立康唑对映异构对b的拆分方法
TW202423418A (zh) * 2022-09-30 2024-06-16 大陸商上海濟煜醫藥科技有限公司 雙環類化合物的無定形、結晶固體及其製備方法
CN119798219B (zh) * 2025-01-13 2025-07-18 长治医学院 一种奥特康唑的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203936A (zh) * 2011-12-11 2014-12-10 威尔金制药有限公司 金属酶抑制剂化合物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
CS228931B2 (cs) 1981-06-06 1984-05-14 Pfizer Způsob výroby 2-(2,4-difluorfenyl)-l,3-bis(lH-l,2,4-triazol-l-yl)propan- -2-oiu
GB8304282D0 (en) 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
KR20040050906A (ko) * 2001-10-08 2004-06-17 코닌클리케 필립스 일렉트로닉스 엔.브이. 모션 추정을 위한 장치 및 방법
JP2004359646A (ja) 2003-06-09 2004-12-24 Ss Pharmaceut Co Ltd 抗真菌活性を有する新規アゾール誘導体
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
CN102803232A (zh) 2009-06-18 2012-11-28 巴斯夫欧洲公司 杀真菌的具有5-硫取代基的1,2,4-三唑衍生物
HRP20160172T1 (hr) 2010-04-24 2016-05-06 Viamet Pharmaceuticals, Inc. Spojevi koji su inhibitori metaloenzima
CN103781775B (zh) 2011-06-19 2016-11-16 威尔金制药有限公司 金属酶抑制剂化合物
WO2012177603A2 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012273004B2 (en) 2011-06-23 2017-04-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
EA201491386A1 (ru) 2012-01-20 2014-11-28 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
IN2014DN06792A (OSRAM) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
KR20140012226A (ko) * 2012-07-18 2014-02-03 엘지전자 주식회사 태양전지 모듈
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
EP3004067A4 (en) 2013-05-28 2016-10-12 Viamet Pharmaceuticals Inc FUNGICIDE COMPOSITIONS
AU2014278172B2 (en) 2013-06-12 2018-08-09 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP3119754A4 (en) * 2014-03-19 2017-12-13 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2015143166A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
WO2015143162A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2015143154A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
EP3119745B1 (en) * 2014-03-19 2020-08-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942927A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
SI3271347T1 (sl) 2015-03-19 2022-11-30 Mycovia Pharmaceuticals, Inc. Protiglivične spojine in postopki za izdelavo
WO2016187201A2 (en) 2015-05-18 2016-11-24 Viamet Pharmaceuticals, Inc. Antifungal compounds
WO2017049096A1 (en) 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Antifungal compound process
BR112018009920A2 (pt) 2015-11-17 2018-11-13 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorfenil)-1,1-diflúor-2-hidróxi-3-(1h-1,2,4-triazol-1-il)propil)piridin-3-il)óxi)benzonitrila e processos de preparação
KR20180101343A (ko) 2015-11-17 2018-09-12 다우 아그로사이언시즈 엘엘씨 4-((6-(2-(2,4-디플루오로페닐)-1,1-디플루오로-2-옥소에틸)피리딘-3-일)옥시)벤조니트릴 및 제조방법
KR20180100313A (ko) 2015-11-17 2018-09-10 다우 아그로사이언시즈 엘엘씨 4-((6-(2-(2,4-디플루오로페닐)-1,1-디플루오로-2-히드록시-3-(1h-1,2,4-트리아졸-1-일)프로필)피리딘-3-일)옥시)벤조니트릴 및 제조방법
EP3377475A4 (en) 2015-11-17 2019-04-10 Dow Agrosciences Llc 4 - ((6-2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-YL) PROPYL) PYRIDINE-3-YL ) OXY) BENZONITRIL AND METHOD OF PREPARING THEREOF
MX376201B (es) 2015-12-30 2025-03-07 Nqp 1598 Ltd Compuestos inhibidores de metaloenzima.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203936A (zh) * 2011-12-11 2014-12-10 威尔金制药有限公司 金属酶抑制剂化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 2007年5月梁峻銘之研究論文「以一般化結晶技術篩選藥物多晶型的研究」 *

Also Published As

Publication number Publication date
TW201718541A (zh) 2017-06-01
US20190194160A1 (en) 2019-06-27
EA201890522A1 (ru) 2018-08-31
CA2998805C (en) 2023-09-26
US10836740B2 (en) 2020-11-17
EA201890752A1 (ru) 2018-08-31
US20180265492A1 (en) 2018-09-20
HK1258862A1 (zh) 2019-11-22
EP3349586A4 (en) 2019-04-17
JP6887993B2 (ja) 2021-06-16
JP2018529687A (ja) 2018-10-11
MX2018003357A (es) 2018-08-16
AU2016323782A1 (en) 2018-03-22
KR20180100297A (ko) 2018-09-10
CA2998807A1 (en) 2017-03-23
US10464921B2 (en) 2019-11-05
EP3349587B1 (en) 2020-07-22
US10513505B2 (en) 2019-12-24
EP3349587A1 (en) 2018-07-25
HK1257225A1 (en) 2019-10-18
EP3349586B1 (en) 2020-12-02
HK1263287A1 (zh) 2020-03-20
EP3349753A4 (en) 2019-01-23
WO2017049196A1 (en) 2017-03-23
JP6847458B2 (ja) 2021-03-24
AU2016323782B2 (en) 2020-11-26
KR102798709B1 (ko) 2025-04-23
BR112018005194A2 (pt) 2018-10-09
AU2016324148A1 (en) 2018-03-15
EP3349587A4 (en) 2019-04-24
MX2018003280A (es) 2018-08-16
EA037521B1 (ru) 2021-04-07
CN108289457A (zh) 2018-07-17
MX391538B (es) 2025-03-21
ES2821021T3 (es) 2021-04-23
WO2017049096A1 (en) 2017-03-23
EA201890751A1 (ru) 2018-08-31
CA2998808A1 (en) 2017-03-23
JP2018532719A (ja) 2018-11-08
TWI730986B (zh) 2021-06-21
AU2016323767A1 (en) 2018-03-15
CN108348511A (zh) 2018-07-31
ZA201801404B (en) 2018-12-19
TW201718540A (zh) 2017-06-01
BR112018005198A2 (pt) 2018-10-09
AU2016324148B2 (en) 2020-10-29
EP3349586A1 (en) 2018-07-25
WO2017049080A1 (en) 2017-03-23
TWI723047B (zh) 2021-04-01
EA036098B1 (ru) 2020-09-28
CA2998805A1 (en) 2017-03-23
CN108347949A (zh) 2018-07-31
PL3349586T3 (pl) 2021-05-31
JP2018527367A (ja) 2018-09-20
US20180258068A1 (en) 2018-09-13
EA038214B1 (ru) 2021-07-23
AU2016323767B2 (en) 2020-10-15
US20200024252A1 (en) 2020-01-23
JP2021121606A (ja) 2021-08-26
MX391539B (es) 2025-03-21
HK1258863A1 (zh) 2019-11-22
BR112018005194B1 (pt) 2022-11-08
US10308632B2 (en) 2019-06-04
MX2018003284A (es) 2018-08-23
TW201718497A (zh) 2017-06-01
EP3349753A1 (en) 2018-07-25
ES2858314T3 (es) 2021-09-30
CN108347949B (zh) 2021-08-13
KR20180052755A (ko) 2018-05-18
CN108289457B (zh) 2021-08-06
KR20180053393A (ko) 2018-05-21
HUE053638T2 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
TWI766842B (zh) 抗真菌化合物及其製備方法
US10676459B2 (en) Antifungal compounds and processes for making
CN109970629B (zh) 抗真菌化合物的制备方法
HK1246798B (en) Antifungal compounds and processes for making
HK1246798A1 (en) Antifungal compounds and processes for making
HK1234744B (zh) 抗真菌化合物的制备方法
HK1263288B (en) Antifungal compound process
HK1263288A1 (en) Antifungal compound process

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees